Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Esperion Therapeutics (NASDAQ:ESPR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $9.00 price target on the stock.
Why Analysts Are Rewriting Esperion's Story After New Pipeline Results and Global Partnerships [Yahoo! Finance]
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference